All In Biotech

Drug Trial Radar · NCT04159805

A Study of TAK-079 in People With Generalized Myasthenia Gravis

A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Jun 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Jan 14, 2020

Primary completion

Jul 12, 2022

Study completion Jul 12, 2022

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles. TAK-079 is a medicine to help people with generalized myasthenia gravis. The main aim of this study is to check if people with generalized myasthenia gravis have side effects from 2 doses of TAK-079. Other aims are to learn if TAK-079 improves their clinical condition and lowers their autoantibody levels. At the first visit, the study doctor will check if each person can take part. For those who can take part, participants will continue with their standard medicines for this condition during the study. Each participant will have a check-up by the study doctor. Then, the participants will have 1 of 3 treatments: * A low dose of TAK-079. * A high dose of TAK-079. * A placebo. In this study, a placebo looks like TAK-079 but does not have any medicine in it. Participants will not know which treatment they received, nor will their study doctors. This is to help make sure the results are more reliable. For each treatment, participants will receive injections just under the skin, once a week for 8 weeks. The study doctors will check for side effects from the study treatments. The study doctors can stop or delay the injections in each participant if needed. Then, the study doctors will continue to check for side effects for up to 24 weeks after treatment. They will also check the clinical condition of the participants, including their autoantibody levels.

Conditions

  • Myasthenia Gravis

Interventions

  • TAK-079Drug

    TAK-079 subcutaneous injection

  • TAK-079 PlaceboDrug

    TAK-079 placebo-matching subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 or Higher TEAEs, and Adverse Event (AE) Leading to TAK-079 DiscontinuationTime frame: From signing the informed consent form up to end of long-term follow-up (up to Week 32)

Locations

50 sites in 6 countries. Site status is shown where the registry gives one.

  • The University of Arizona Medical Center

    Tucson, Arizona

  • Stanford Neuroscience Health Center

    Palo Alto, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of Colorado Hospital

    Aurora, Colorado

  • George Washington University

    Washington D.C., District of Columbia

  • SFM Clinical Research, LLC

    Boca Raton, Florida

  • Neurology Associates PA

    Maitland, Florida

  • Medsol Clinical Research Center Inc

    Port Charlotte, Florida

  • Augusta University

    Augusta, Georgia

  • Consultants In Neurology

    Northbrook, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Wayne State University

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Michigan State University

    East Lansing, Michigan

  • Neurology and Sleep Disorders Clinic

    Columbia, Missouri

  • Hospital For Special Surgery

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Carolinas HealthCare System Neurosciences Institute-Neurology

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Ohio State University Medical Center

    Columbus, Ohio

  • Austin Neuromuscular Center

    Austin, Texas

  • The University of Texas South Western Medical Center

    Dallas, Texas

  • Central Texas Neurology Consultants PA

    Round Rock, Texas

  • Center for Neurological Disorders

    Milwaukee, Wisconsin

  • The Medical College of Wisconsin, Inc.

    Milwaukee, Wisconsin

  • The Governors of the University of Calgary

    Calgary, Alberta, Canada

  • Vancouver General Hospital (VGH)

    Vancouver, British Columbia, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • IRCCS AOU San Martino

    Genova, Italy

  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta

    Milan, Italy

  • Azienda Ospedaliera Sant'andrea

    Rome, Italy

  • Fondazione Policlinico Universitario A Gemelli

    Rome, Lazio, Italy

  • Centrum Medyczne NeuroProtect

    Warsaw, Poland

  • Centrum Medyczne Warszawa - PRATIA - PPDS

    Warsaw, Poland

  • Neurocentrum Bydgoszcz sp. z o.o.

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Centrum Neurologii Klinicznej Sp. z o.o.

    Krakow, Lesser Poland Voivodeship, Poland

  • Clinical Center of Serbia - PPDS

    Belgrade, Serbia

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.